Logo
Search

Rules:

Only words with 2 or more characters are accepted
Max 200 chars total
Space is used to split words, "" can be used to search for a whole string (not indexed search then)
AND, OR and NOT are prefix words, overruling the default operator
+/|/- equals AND, OR and NOT as operators.
All search words are converted to lowercase.

Search for "pharmacokinetic"

Displaying results 1 to 7 out of 7

  2010-2017 81%
  ... Y, Rajman I, Canadi J, Dahlke M, Lloyd P, Halabi A. Pharmacokinetics of serelaxin in patients with hepatic impairment: A ... M, Huang F. Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers. J Clin Pharmacol. 2014 Oct ... B, Halabi A , Petersen-Sylla M , Yong CL, Elgadi M.,
  Size: 65 K - Created: 09-11-15 - Modified: 27-07-17 10:05
Path: /Expertise/Published Expertise/2010-2017

  1990 – 1999 78%
  ... J, Halabi A , Kleinbloesem CH, Heinig R, Blume H. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase ... KM, Roots I. No effect of liver impairment on the pharmacokinetics of levetiracetam. Eur J Clin Pharmacol 1999 ; 55:No. ... Kurowski M, Eckl KM. Voglibose has no effect on the
  Size: 61 K - Created: 18-11-12 - Modified: 20-06-17 17:09
Path: /Expertise/Published Expertise/1990 – 1999

  2000 – 2009 76%
  ... Giersbergen PL. Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan. J Clin ... H, Bias P, Maly AK, Siegler KE, Mehltretter K. Pharmacokinetic and pharmacodynamic profile of new biosimilar ... A, Ortland C. Fluorescence characteristics and pharmacokinetic properties of a novel self-adhesive 5-ALA patch for ...
  Size: 53 K - Created: 09-11-15 - Modified: 20-06-17 17:09
Path: /Expertise/Published Expertise/2000 – 2009

  Info-Point 75%
  ... - The Largest Phase I/II Clinic for large-scale, long-term and challenging trials Flyer Your First Address in Europe For Renal Impairment Pharmacokinetics Flyer Your Preferred Partner In Europe For Clinical Trials In Hepatic Impaired Patients Flyer Aging Population - A Challenge In Drug ...
  Size: 39 K - Created: 18-11-12 - Modified: 20-06-17 17:09
Path: /Info-Point

  Medical Writing 72%
  ... summaries and overviews of Common Technical Documents (CTD)   Development and therapeutic areas: Phase I Clinical pharmacology studies – pharmacokinetics and pharmacodynamics Biologics and biosimilars
  Size: 32 K - Created: 18-11-12 - Modified: 20-06-17 17:09
Path: /Services/Medical Writing

  Early Phase I to IIa 69%
  ... are freshly prepared by trained CRS chefs or delivered by external catering services. Special dietary needs (especially in connection with pharmacokinetic profile days, food-drug interaction studies and the long-term nutrition of hospitalised subjects) can be easily met without affecting ...
  Size: 32 K - Created: 18-11-12 - Modified: 20-06-17 17:09
Path: /Services/Early Phase I to IIa

  1981 – 1989 66%
  ... Texas/USA, November 8-11, 1989 Bickel U, Thomsen T , Fischer JP, Kewitz H. Galanthamine: pharmacokinetics and inhibition of cholinesterases in humans. In: Kewitz H, Thomsen T , Bickel U, (eds): ... 30 – June 1, 1989 , Toronto, Canada. Clin Biochem; 22:411. Thomsen T , Bickel U, Kewitz H. Pharmacokinetic and pharmacodynamic data for galanthamine in the treatment of Alzheimer's disease. Berlin ...
  Size: 42 K - Created: 18-11-12 - Modified: 20-06-17 17:09
Path: /Expertise/Published Expertise/1981 – 1989

FooterEnd